Status:
RECRUITING
Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients
Lead Sponsor:
Peking University People's Hospital
Conditions:
HER2-positive Early Breast Cancer
Eligibility:
FEMALE
18-75 years
Phase:
PHASE1
PHASE2
Brief Summary
Neoadjuvant treatment is an important treatment for early breast cancer patients. Patients with her2 enriched subtype who achieved pCR after neoadjuvant treatment would have longer survival. The neoad...
Detailed Description
Neoadjuvant chemotherapy for breast cancer could make unresectable breast cancer be resectable and improve breast conservation rate. Patients with her2 enriched subtype who achieved pCR after neoadjuv...
Eligibility Criteria
Inclusion
- invasive breast cancer
- HER2 positive
- T2 or node positive
- ECOG 0-1
Exclusion
- stage IV
- inflammatory breast cancer
- Severe chronic disease
Key Trial Info
Start Date :
March 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04750122
Start Date
March 28 2021
End Date
December 31 2026
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People'S Hospital
Beijing, Beijing Municipality, China, 100044